- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Advantages of Bempedoic Acid in Cardiovascular Disease Treatment Landscape
In their final thoughts, the experts illustrate the overall effect of bempedoic acid for statin-intolerant patients with atherosclerotic cardiovascular disease.
EP: 1.CLEAR Outocmes Trial Overview: Non-Statin Therapies for Patients with Atherosclerotic Cardiovascular Disease (ASCVD)
EP: 2.Mechanism of Action: Bempedoic Acid vs Statins
EP: 3.Examining CLEAR Outcomes Trial Structure
EP: 4.Key Data Analysis from CLEAR Outcomes Trial
EP: 5.Adverse Event Profile of Bempedoic Acid
EP: 6.Advantages of Bempedoic Acid in Cardiovascular Disease Treatment Landscape
Leslie Cho, M.D., FACC, FESC, FSCAI: When you talk to your patients, other clinicians, managed care professionals, and decision-makers, where do you think eventually this drug will come into play? Do you think this will be before PCSK9 or after, or if they refuse PCSK9? What do you think?
Seth S. Martin, M.D., M.H.S., FACC, FAHA, FASPC: It feels to me like it’s a consideration alongside PCSK9 and is on the same level because you have to factor in that oral versus injectable preference that patients have. It’s just a nice opportunity, as we have those discussions with patients in clinic to provide multiple options, which, by the way, is an incredibly wonderful thing to be able to do now, when in the past, all we had were statins and some older therapies. It’s really nice to have these options. It’s a fun discussion to have with patients. Here are the different options you have. I think it should probably be introduced pretty early in the discussion, especially because it also can be paired together with ezetimibe [Zetia], as we’ve talked about. I would be having it alongside the discussions for PCSK9 inhibitors.
Leslie Cho, M.D., FACC, FESC, FSCAI: Yeah. I agree with you. That’s a very nice way to think about it. With that, we are going to close our discussion on CLEAR Outcomes. I want to thank you for joining us today. And I want to thank Dr Seth Martin from Johns Hopkins Hospital [Baltimore, Maryland] for also providing a wonderful discussion.
Seth S. Martin, M.D., M.H.S., FACC, FAHA, FASPC: Thank you, Dr Cho.
Leslie Cho, M.D., FACC, FESC, FSCAI: Thank you.
Transcript edited for clarity.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
